Job DescriptionPosition Description:
A research opportunity is available at the U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Office of Pharmaceutical Quality (OPQ) / Office of Testing and Research (OTR) located in St. Louis, Missouri. This position is co-sponsored by Office of Generic Drug (OGD). The appointment is full-time. The initial term is for one year, but may be renewed upon recommendation of FDA contingent on the availability of funds. The participant will receive a monthly stipend commensurate with educational level and experience.
The research fellow will perform laboratory-based study in support of regulatory science research in synthetic oligonucleotide therapeutics. Specifically, the research will focus on developing high resolution mass spectrometry (HRMS)-based method to apply to oligonucleotide and impurity analysis. The fellow will utilize liquid chromatography, HRMS and tandem MS in conjunction with various software and bioinformatics to develop and validate analytical methods.
The qualified candidate should have received a Ph.D. degree in Chemistry, Biochemistry, or a related field, or be currently pursuing the degree. Degree must have been received within the last 60 months or anticipated to be received by 9/30/2021.
• Strong analytical experience in liquid chromatography, and orbitrap/time-of-flight/ion mobility mass spectrometry.
• Strong analytical knowledge and problem solving skills in characterization, identification and quantification by mass spectrometry.
• Research experience and knowledge in oligonucleotides (or peptides) and impurity analysis.
• Familiarity with MS data processing software.
US citizenship, green card, EAD, OPT or CPT is required. An H1 visa cannot be sponsored for this position nor can an OPT extension be obtained.
How to Apply:
Qualified individuals should submit a copy of their CV and a one-page summary of their research experience and career goal to Dr. Kui Yang via email (firstname.lastname@example.org) with a Subject “2021 FDA Oligo Fellowship”. Interview is on a rolling basis.